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FACS analysiscould lead to a better understanding of BRCA1-associated oncogenic events and could
prove valuable in clinical testing for BRCA1-involvement in patients.
Methods: For this purpose, genomic and gene expression profiles of basal-like BRCA1-
mutated breast tumors (n ¼ 27) were compared with basal-like familial BRCAX (non-
BRCA1/2/CHEK2*1100delC) tumors (n ¼ 14) in a familial cohort of 120 breast carcinomas.
Results: Genome wide copy number profiles of the BRCA1-mutated breast carcinomas in our
data appeared heterogeneous. Gene expression analyses identified varying amounts of tu-
mor infiltrating lymphocytes (TILs) as a major cause for this heterogeneity. Indeed, select-
ing tumors with relative low amounts of TILs, resulted in the identification of three known
but also five previously unrecognized BRCA1-associated copy number aberrations. More-
over, these aberrations occurred with high frequencies in the BRCA1-mutated tumor sam-
ples. Using these regions it was possible to discriminate BRCA1-mutated from BRCAX
breast carcinomas, and they were validated in two independent cohorts. To further sub-
stantiate our findings, we used flow cytometry to isolate cancer cells from formalin-
fixed, paraffin-embedded, BRCA1-mutated triple negative breast carcinomas with esti-
mated TIL percentages of 40% and higher. Genomic profiles of sorted and unsorted frac-
tions were compared by shallow whole genome sequencing and confirm our findings.
Conclusion: This study shows that genomic profiling of in particular basal-like, and thus
BRCA1-mutated, breast carcinomas is severely affected by the presence of high numbers of
TILs. Previous reports on genomic profiling of BRCA1-mutated breast carcinomas have
largely neglected this. Therefore, our findings have direct consequences on the interpre-
tation of published genomic data. Also, these findings could prove valuable in light of
currently used genomic tools for assessing BRCA1-involvement in breast cancer patients
and pathogenicity assessment of BRCA1 variants of unknown significance. The BRCA1-
associated genomic aberrations identified in this study provide possible leads to a better
understanding of BRCA1-associated oncogenesis.
ª 2015 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights
reserved.1. Introduction et al., 2011). Nevertheless, the observed similarities betweenBreast tumors of BRCA1 germ linemutation carriers have been
shown to be primarily of the basal-like subtype (75e90%)
(Sorlie et al., 2003; Jonsson et al., 2010). These basal-like breast
carcinomas (BLCs) represent about 10e20% of all breast carci-
nomas (Foulkes et al., 2003; Sorlie et al., 2003) and are generally
high grade, triple negative ((ER-), (PR-), and (HER2/ERBB2-)
and express high molecular weight cytokeratins (CK5/6, 14
and 17) (Lakhani et al., 2002; Foulkes et al., 2003; Honrado
et al., 2005; Rubinstein, 2008).
High levels of genomic instability are frequently observed
in BRCA1-mutated carcinomas and BLCs in general, both spo-
radic and hereditary (Bergamaschi et al., 2006; Jonsson et al.,
2010; Smid et al., 2010). Although frequent, these genomic ab-
errations mostly represent low copy number gains and losses
of large DNA segments rather than (focal) high level amplifica-
tions (Bergamaschi et al., 2006; Stefansson et al., 2009). This
observation fits well with the described role of BRCA1 in DNA
damage response andDNArepair throughhomologous recom-
bination (HR) (Roy et al., 2012). Hyper-methylation of the
BRCA1 promoter region and reduced BRCA1mRNA expression
levels have been observed in sporadic BLCs and could act as an
alternative mechanism of BRCA1 inactivation (Wei et al., 2005;
Birgisdottir et al., 2006; Turner and Reis-Filho, 2006). However,
the involvement of a dysfunctional BRCA1 gene in sporadic
BLCs has also been questioned due to lack of somatic muta-
tions in the BRCA1 gene (Futreal et al., 1994; Gonzalez-AnguloBRCA1-mutated andnon-mutated BLCshave led to the sugges-
tion that targeting a dysfunctional BRCA1-pathway, exploiting
in particular a defective HR, might be effective in all BLCs
(Turner et al., 2004). However, platinum based chemotherapy
and treatments with PARP inhibitors have shown inconsistent
results in BLCs (Silver et al., 2010; Lips et al., 2011a). For this
reason, the role of a dysfunctional BRCA1 gene or pathway as
a general characteristic of BLCs remains uncertain.
To allow discrimination between BRCA1-mutated and un-
selected sporadic/hereditary breast tumors, micro-array
based comparative genomic hybridization studies (aCGH)
have been used to identify characteristic genomic aberrations
in BRCA1-mutated breast tumors (Tirkkonen et al., 1997;
Wessels et al., 2002; van Beers et al., 2005; Jonsson et al.,
2005; Joosse et al., 2009). Recent studies comparing BLCs
with and without BRCA1 mutations have reported few or
even no differential regions of genomic aberrations
(Stefansson et al., 2009; Jonsson et al., 2010; Waddell et al.,
2010). A well known difficulty in DNA-copy-number determi-
nation by aCGH and SNP array analyses is variable tumor pu-
rity due to normal DNA contamination. In literature, a number
of approaches have been proposed to try tomitigate this effect
(Yau et al., 2010). However, such methods have not been
applied in aforementioned genomic profiling efforts of
BRCA1-mutated breast carcinomas.
The use of BRCA1 specific classifiers would facilitate the
identification of women and their family members with
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mutations. They might also prove valuable in assessing the
pathogenicity of variants of unknown clinical significance
(Joosse et al., 2009). Furthermore, the identification of driver
genes in regionscharacteristic forBRCA1-mutated tumors could
lead to a better understanding of the underlying process of
oncogenesis andmayprovidenovel clues for targeted therapies.
The aim of this study was to identify characteristic copy
number aberrations (CNAs) for BRCA1-mutated breast. For
this reason single nucleotide polymorphism (SNP) array data
and gene expression data for 120 hereditary breast tumors
were analyzed. As the majority of the BRCA1-mutated breast
carcinomas are found to be of the basal-like subtype, our pri-
mary analysis was restricted to BLCs. Initially, comparison of
27 BRCA1-mutated versus 14 BRCAX BLCs did not show clear
CNAs characteristic for the BRCA1-mutated BLCs. However,
optimal sample selection of tumors with low amounts of
TILs allowed for the identification of three known and five
novel BRCA1-associated CNAs capable of discriminating be-
tween BRCA1-mutated and BRCAX BLCs.2. Materials and methods
2.1. Ethics statement
This study has been approved by the medical ethical commit-
tee at Erasmus MC, and was performed according the Code of
Conduct of the Federation of Medical Scientific Societies in
The Netherlands.
2.2. Sample collection
Fresh-frozen specimens of primary breast tumors from female
familial breast cancer caseswere selected from the tissuebank
of theErasmusMedical CenterRotterdam. In this study, 120 tu-
mor samples for which both SNP array and gene expression
data is available were used for further analyses. The entire
cohort of 154 samples has been described previously (Nagel
et al., 2012). The gene expression and SNP microarray data
have been deposited in NCBI’s Gene Expression Omnibus and
are accessible through GEO Series accession number 54219.
For validation purposes three publicly available datasets
were used (Supplemental Figure S1). These are: 1.) 118 BLCs
selected from the discovery dataset of this study on sporadic
breast carcinomas (Curtis et al., 2012) to study the effect of
high numbers of TILs on copy number calling, 2.) 359 primary
breast tumors, including 18 BRCA1-mutated BLCs, for which
aCGH and gene expression data is available (Jonsson et al.,
2010), used for validation of BRCA1-associated CNAs and the
TIL gene expression profile, and 3.) 186 samples including 40
BRCA1-mutated breast tumors for which aCGH data and he-
matoxylin and eosin stained (H&E) sections of paraffin-
embedded tissue is available, obtained from the Netherlands
Cancer Institute (Schouten et al., 2013) used for further valida-
tion of BRCA1-associated CNAs. For FACS sorting, archival,
formalin-fixed, paraffin-embedded, (FFPE) germ line BRCA1-
mutated triple negative breast tumors were obtained from
the FFPE tissue bank of the Department of Pathology, VUMC,
Amsterdam, The Netherlands. Samples were handledaccording to the medical ethical guidelines described in the
Code for Proper Secondary Use of Human Tissue established
by the Netherlands Federation of Medical Sciences.
2.3. Mutation screening
BRCA1, BRCA2 and CHEK2*1100delC mutation screening has
been described (Nagel et al., 2012).
2.4. Gene expression microarrays
Affymetrix hgU133_Plus_2.0 GeneChips based expression data
have been previously described (Nagel et al., 2012). The gene
expression data have been deposited in NCBI’s Gene Expres-
sion Omnibus and are accessible through GEO Series acces-
sion number 54219. The data was analyzed in Partek
Genomics Suite (v6.6, Partek Inc.).
2.5. Classification of intrinsic molecular subtypes
The intrinsic gene list was used to appoint the samples to mo-
lecular subtypes as described (Smid et al., 2008). In short, the
intrinsic gene list (Perou et al., 2000) was mapped to the corre-
sponding probe-sets on the hgU_133_plus_2.0 array using
Unigene Cluster Id’s. The most variable probe-sets were
used to cluster 120 familial samples using average linkage hi-
erarchical clustering with correlation as a distance metric.
2.6. Copy number analyses by SNP arrays
The array intensity CEL files for 120 breast tumor samples,
including 35 BRCA1, five BRCA2, 17 CHEK2*1100delC mutated
and 63 BRCAX tumor samples were processed by Partek Geno-
mics Suite using default settings for background correction
and summarization, results were corrected for GC-content
and fragment length. Unpaired copy number analysis was
performed in Partek Genomics Suite, comparing signal Log2
ratios to a custom created reference baseline of 90 female
HapMap CEPH samples with European ancestry (CEU). The
genomic segmentation algorithm was used to detect break-
point regions and estimate copy number levels with stringent
parameters (P < 0.0001, >20 markers, signal/noise: 0.45). With
an expected normal range of 2  0.25 copies. Differences be-
tween the tumor groups (mutation class) for frequency of
copy number aberrations (gained, lost, or unchanged) were
calculated by employing a 3  2 Fisher’s exact test (FE). Result-
ing p-values were not directly corrected for multiple testing.
SNP array, gene and cytogenetic band locations are based on
the hg18 Genome build.
For unsupervised hierarchical clustering of copy number
data the called copy number states (gain, loss or neutral) of
the segmentation data were used as distance metric. Agglom-
erative clustering was performed on these data by Euclidean
distance and Wards method.
Identical settings for copy number analysis were applied in
the validation cohorts. However, for validation dataset 3, the
overall signal intensities of the samples (run on aCGH plat-
form as opposed to SNP arrays in our primary study) was
lower compared to the samples of the primary study. There-
fore, copy number segmentation was also performed with
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range of 2  0.20) resulting in more samples passing the
CNA calling criteria and being suited for BRCA1 classification.
Gene expression profiling was not performed on these sam-
ples. Further analyses were performed on samples for which
hormone receptor status information was available. Details
for correlating copy number and gene expression data can
be found in Supplemental File S2.
2.7. LOH calling by detection of allelic imbalance
A segmentation based approach of allelic imbalances was
used to identify regions of loss of heterozygosity (LOH). The
B-allele frequencies of 120 breast tumor samples were gener-
ated in Partek Genomics Suite. Mirrored BAF profiles (mBAF)
were used as previously described (Staaf et al., 2008). The
resulting mBAF profiles were segmented in Partek Genomics
Suite and LOH calling of segmented regions was done by
applying a fixed allelic imbalance threshold of 0.76 and p-
value <0.01. The same parameters used in segmentation of
the copy number data were applied, except that a window
size of 100 SNPs instead of 20 SNPs was used as a minimum
number of genomic markers.
2.8. Analysis of BRCA1 promoter methylation
BRCA1 promoter hyper-methylation was determined by
methylation-specific PCR (MSP) after bisulfite treatment of
DNA. Bisulfite modification of DNA to convert unmethylated
cytosine residues to uracil was carried out using the EZ DNA
methylation kit (Zymo Research, Orange, CA) following the
manufacturer’s protocol. A genomic DNA control sample
was used as a negative control, and the same sample treated
in vitro with SssI bacterial methylase was used as a positive
control. Primer sequences were adapted from Wei et al. (Wei
et al., 2005). The PCR reactionwas composed of an initial dena-
turation at 95 C for 5 min, followed by 37 cycles consisting of
30 s at 95 C, 30 s at 61 C, 45 s at 72 C and ending with a final
5 min extension at 72 C. The PCR products were analyzed by
electrophoresis and UV transillumination.
2.9. Scoring of TILs in tumor sections
H&E stained frozen and FFPE sections were scored for the
amount of infiltrating lymphocytes in the tumor by experi-
enced pathologists from the respective institutes. This was
performed by estimating the number of lymphocytes, and re-
ported as a percentage of all nuclei present within that area.
2.10. Scoring BRCA1-associated genomic aberrations
To discriminate between BRCA1-mutated and BRCAX BLCs, a
class prediction algorithm using a nearest shrunken centroid
methodology with equal priors, imbedded in Partek Genomics
Suite software, was applied. As input, mean copy number
values from the segmentation results were used. Genomic re-
gions used by this algorithm were found to overlap with the
most significant regions as reported in the Fisher’s exact test
results. These regions in combination with the most
frequently observed genomic aberrations present in all BLCswere used to define 12 regions of BRCA1-BLC associated copy
number aberrations. These specific regions of copy number
loss or gain were analyzed in cross platform validation data-
sets. Samples were scored for the amount of copy number ab-
errations (gains/losses) in these regions, when 9 or more
regions harbor similar CNAs as determined for the BRCA1-
mutated BLCs, samples are called as BRCA1-like. This
threshold of 9 or more was chosen based on the primary data-
set whereby all cases with low immune-infiltrate levels of
BRCA1-mutated origin were scored as BRCA1-like. For the
Netherlands Cancer Institute validation set, samples were
coded and results were disclosed after CNA scoring.
2.11. Tumor dissociation and DNA flow cytometry
H&E-stained paraffin sections taken from 10 selected triple
negative BRCA1-mutated breast tumor samples were scored
by an experienced pathologist to determine the extent of TILs.
Five samples with the highest amount of TILs (>40%) were
selected for further analysis. Sample processing and FACS sort-
ing was performed as described previously with minor modifi-
cations (Corver et al., 2005; Corver and ter Haar, 2011) for
details see (Supplemental File S2). After sorting, DNA was iso-
lated using the Promega,Wizard Genomic DNA Purification kit.
2.12. Copy number profiling by shallow whole genome
sequencing
DNA derived from three cellular fractions isolated from three
germ line BRCA1-mutated breast carcinomas was sequenced
at low coverage depth (w0.1e0.3 fold, for detailed sequencing
statistics see Supplemental File S3). In total, 100e200 ng of
DNA (depending on availability) was used for library prepara-
tion with the Illumina TruSeq DNA v2 kit, as described previ-
ously (Smeets et al., 2011; van Thuijl et al., 2013). Bar-coded
libraries were pooled and run on an Illumina HiSeq 2500
(San Diego, CA, USA) for single end 50 cycle (SR50) sequencing.
Sequencing reads were aligned to the human reference
genome (build GRCh37/hg19) with BWA (Li and Durbin, 2009)
and PCR duplicates as well as ambiguous reads were filtered
out. Next, the genome was divided into non-overlapping
bins of 15 kbp, and the number of reads in each bin was
counted. These counts were 1.) corrected (using GC content
and mappability) and 2.) filtered using a blacklist derived
from ENCODE data (Bernstein et al., 2012) and 1 KG (Abecasis
et al., 2012), 3.) log2-transformed, 4.) median normalized, 5.)
segmented, and called with Partek Genomics Suite similarly
as described for the SNP array CNA analysis. The hg18 based
genomic coordinates of the BRCA1-associated CNAs were
mapped to the hg19 genome build using the hg-Liftover tool
from UCSC (http://genome.ucsc.edu/). Copy number profiles
are plotted using ggplot2 software (Wickham, 2009).3. Results
3.1. BRCA1 status and intrinsic sub-typing
Gene expression and SNP array analyses were performed on
120 familial breast carcinomas. The cohort consists of 35
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mutated and 63 BRCAX carcinomas without such mutations,
referring to as BRCAX. In accordance with literature, 77% of
the BRCA1-mutated carcinomas (n ¼ 27) in this study are of
the basal-like subtype. In accordance with the incidence of
basal-like cancers amongst breast cancer in general, 14 out
of 63 (22%) BRCAX breast carcinomas are of the basal-like sub-
type (Waddell et al., 2010). The remainder of BRCA1-mutated
breast carcinomas is predominantly of the luminal-B subtype;
see Supplemental file S4 for complete sample information. Ev-
idence for BRCA1 promoter hyper-methylation was detected
for six samples by MSP, amongst which three BRCAX tumors
of the basal-like subtype.
3.2. Tumor infiltrating lymphocytes affect genomics
analyses
To gain insight into the genomic characteristics of BRCA1-
mutated breast carcinomas, copy number and LOH profiling
based on high-resolution SNP arrays was performed.
Copy number profiles for most of the BRCA1-mutated tu-
mors, and basal-like carcinomas (BLCs) in general, showed
many CNAs. Supervised comparison of the copy number pro-
files of the BRCA1-mutated BLCs versus BRCAX BLCs resulted
in very few regions of copy number difference. Although
few, these regions are in accordance with previous reports
(Joosse et al., 2009). Regions include CNAs on chromosome 3
and copy number loss on chromosomal arm 15q (data not
shown). This is in line with the unsupervised hierarchical
clustering results showing clustering of the majority of BLCs
in two groups irrespective of mutational status (Figure 1A).
One group (Figure 1A, group 1; high CIN) is characterized by
many CNAs and tight co-segregation and a second group
(Figure 1A, group 2; low CIN) with markedly fewer CNAs that
cluster more loosely within the bulk of the luminal samples.
As shown in Figure 1B, regions with loss of heterozygosity
(LOH) were frequently identified in group 1 BLCs and only
very few in the group 2 BLCs. This marked difference was
also seen for LOH at the BRCA1egene locus on chromosome
17 in BRCA1-mutated BLCs. Only 9 out of the 27 BRCA1-
mutated BLCs showed LOH at the BRCA1-locus; six with copy
neutral LOH and three with copy number gains and LOH. For
subsequent analyses the group 1 tumorswere therefore subdi-
vided based on LOHat the BRCA1 locus, group 1-Iwith LOHand
group 1-II without LOH. In comparison with the group 1-II tu-
mors (n ¼ 10) and the group 2 tumors (n ¼ 8), the 9 group 1-I
tumors displayed highest frequency of CNAs common to all
groups as well as CNAs in general, see Figure 1C.
Analyzing gene expression of BRCA1-mutated BLCs by
means of ANOVAwith LOH at the BRCA1 locus as single factor
resulted in 618 differentially expressed probe-sets passing a
step-up FDR p-value of 0.05 (Supplemental File S5). Gene
ontology analysis of the 458 uniquely annotated genes using
the DAVID bio-informatics tool (Huang et al., 2009a, 2009b)
identified the term immune response (FDR corrected p-value<
1E-5) to be the most enriched biological process. Tumor infil-
trating lymphocytes (TILs) could explain the above described
results. Indeed, there appeared to be a strong correlation be-
tween the relative amount of the immune signature and
genome-wide measured CNAs, rs ¼ 0.66, p-value< 0.001(Supplemental File S6). Furthermore, assessing the proportion
of lymphocytic nuclei within the tumor samples using H&E-
stained frozen sections showed a significant correlation with
the mRNA based immune signature (rs ¼ 0.74, p-value< 0.01)
(Supplemental File S7).
To confirm the correlation between the TIL mRNA signa-
ture and CNAs in BLCs, we tested this in the discovery set of
a publicly available dataset (Validation dataset 1 in
Supplemental Figure 1; Curtis et al., 2012). The discovery set
contains high resolution SNP array and gene expression data
of 998 primary sporadic breast tumors, including 118 BLCs
which were selected for further analyses. A significant corre-
lation between immune signature and CNA levels was seen
(rs¼0.52, p-value< 0.001). Sampleswith the highest immune
signature levels were found to be amongst those sampleswith
the least reported CNAs, see Supplemental File S8.
3.3. Optimal sample selection
To select for samples with low number of TILs in our cohort,
hierarchical clustering of expression data of all BLCs based
on the immune signature probe-sets was used (Figure 2A).
Following this approach, eight BRCA1 and five BRCAX were
selected for further analysis. These eight BRCA1-mutated
samples all originate from the BRCA1 group with high CIN
with LOH at the BRCA1 locus (Figure 1, group 1-I; n ¼ 9). The
ninth sample from this group was found to have a relative
high TIL immune signature and was therefore not used in
follow-up analyses. Copy number analyses on this selection
of samples resulted in the identification of many CNAs with
frequencies reaching levels of 80e100% for both the BRCA1-
mutated and BRCAX BLCs, somethingwhichwas not observed
in previous studies by others (Tirkkonen et al., 1997; Wessels
et al., 2002; van Beers et al., 2005; Jonsson et al., 2005;
Stefansson et al., 2009; Jonsson et al., 2010; Waddell et al.,
2010). Importantly, multiple regions of significant difference
between the BRCA1-mutated and BRCAX tumors could now
be detected (Figure 2B and C).
3.4. BRCA1-mutated BLC associated genomic
aberrations
Subsequently, a class prediction algorithm using a nearest
shrunken centroid methodology was used to identify eight
genomic regions associated with BRCA1-status. Most of these
regions are similar to the regions identified by the Fischer’s
exact test to be significantly different between the BRCA1-
mutated and BRCAX BLCs. These genomic regions include
three regions previously described in literature, i.e. copy num-
ber gain of the proximal tip of chromosomal arm 3p, copy
number loss of a more distal region on chromosomal arm 3p
and copy number loss of chromosomal arm 15q (Wessels
et al., 2002; Jonsson et al., 2005; van Beers et al., 2005; Joosse
et al., 2009) and five novel regions, i.e. copy number losses at
chromosomal arms 7q, 13q, and 17p and copy number gains
on chromosomal arms 9q and 15q (Tables 1 and 2).
For samples with low amount of TILS these CNAs proved
capable of discriminating between the BRCA1-mutated and
BRCAX BLCs. However, cross-platform applicability of such al-
gorithms is problematic, and since the used sample size was
Figure 1 e Genomic profiles of 120 familial breast carcinomas. A, hierarchical clustering of CNA data. On the vertical axis, chromosomes 1 to X
are displayed. Copy number gains are indicated in red and losses in blue. Subtype, mutation status and methylation of BRCA1 are indicated for
each sample in rows above the cluster plots by color. Group 1 contains the BRCA1 BLC tumors with high CIN and group 2 contains the BRCA1
BLC tumors with low CIN. B, integrated copy number and LOH analysis. Samples are shown as in Figure 1A. In the cluster plot green indicates
copy neutral LOH, red; copy number gain with LOH and blue; copy number loss and LOH. Bottom row above the cluster plot indicates samples
with LOH at the BRCA1 locus (BRCA1 LOH: black). The black arrow within the cluster plot indicates the BRCA1 locus. Group 1 contains
BRCA1 BLCs with high CIN and LOH at the BRCA1 locus (group 1-I samples) and BRCA1 BLCs with high CIN but without LOH at the
BRCA1 locus (group 1-II samples), group 2 contains BRCA1 BLC tumors with low CIN and no detectable LOH at the BRCA1 locus C, the
frequency (vertical axis) of gains (red) and losses (blue) is displayed for the 3 BRCA1 groups mentioned in B.
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Figure 2 e Immune signature based gene expression clustering and comparison of aberration frequencies of selected BRCA1-mutated and BRCAX
BLCs. A, hierarchical clustering of standardized expression data of all BLCs based on the immune signature. Samples from the red branch with
relatively low level of immune signature are selected for further copy number analysis in panel B. Indicated in red and blue are BRCA1-mutated
BLCs with (group 1-I, BRCA1 BLC tumors with high CIN and LOH at the BRCA1 locus, from Figure 1B, n[ 9) and without detectable LOH
(group 1-II, BRCA1 BLC tumors with high CIN without LOH at the BRCA1 locus, and group 2, BRCA1 BLC tumors with low CIN without
LOH at the BRCA1 locus, from Figure 1B, n[ 18) at the BRCA1 locus respectively, green indicates the BRCAX BLCs. B, the frequency (x-axis)
of gains (red) and losses (blue) are displayed along chromosomes 1 to X (y-axis) for 8 BRCA1-mutated (top panel) and 5 BRCAX (bottom panel)
BLCs selected for a low immune signature, red branch in panel A. Note that one BRCA1-mutated BLC with detectable LOH was not used for
further analyses due to a relative high level mRNA immune signature. C, Fisher’s exact test is used to determine regions of differential copy
number aberrations between the BRCA1-mutated and BRCAX BLCs. The dotted line represents a p-value threshold of 0.05 (not corrected for
multiple testing). The regions above the threshold are considered to be significantly different between the groups. P-values are - log 10
transformed.
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a necessity. For this reason we used a simple method appli-
cable to copy number data for all aCGH/SNP platforms, and
copy number data in general. The eight regions mentioned
above together with the four most frequently altered genomic
regions found amongst all BLCs (two regions with copy num-
ber losses on chromosomes 4 and 5, and two with copy num-
ber gains on chromosomes 8 and 10), were used to score
samples and discriminate between BRCA1-mutated BLCs and
all other tumors (Tables 1 and 2). Samples were scored as
described in section 2.10.
In our dataset of 120 familial breast carcinomas, the
BRCA1-mutated BLCs with low TILs were found to have 9 to
12 of these specific CNAs, while all other samples had 8 orTable 1 e BRCA1-associated copy number gains.
Copy number gain
Chromosome Start End
3 3866308 10719396
8a 101981161 129288230
9 94909458 115239031
10a 101955 28140907
15 90224005 97940195
Hg18 based genomic regions of BRCA1-associated CNAs (gains).
a These regions are associated with tumor samples of the basal-
like subtype in general.less (Figure 3). In the BRCA1-mutated BLCs with the highest
amount of immune signature levels no or only very few of
these CNAs are detected. High immune signature mRNA
levels are also found in the three BRCAX BLCs with BRCA1 pro-
moter hyper-methylation, making it difficult to assess a
possible genomic resemblance with BRCA1-mutated BLCs for
these samples.
3.5. Validation of BRCA1-associated CNAs
To validate our findings, a publicly available dataset of 359 pri-
mary breast tumors, including 18 BRCA1-mutated BLCs, forTable 2 e BRCA1-associated copy number losses.
Copy number loss
Chromosome Start End
3 51130455 64449381
4a 24424555 41258860
5a 75800618 86398661
7 102291383 122355559
13 33885792 49037828
15 28016572 41141219
17 6001240 12559716
Hg18 based genomic regions of BRCA1-associated CNAs (losses).
a These regions are associated with tumor samples of the basal-
like subtype in general.
Figure 3 e Scoring of BRCA1-associated CNAs in relation to
immune signature levels. BRCA1-mutated BLCs (red circles) with
low immune signature levels (vertical axis) have a score of 9e12
BRCA1-associated CNAs (horizontal axis). BRCAX BLCs (green
circles) with similar immune signature levels have less of these
BRCA1 specific CNAs. Samples of other subtypes (including BRCA1-
mutated) are indicated by grey circles.
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analyzed (Validation dataset 2 in Supplemental File 1;
Jonsson et al., 2005). A similar immune signature and correla-
tion with genome wide CNAs was identified in this dataset
(Supplemental File S9A).
For all 359 primary breast tumors the amount of BRCA1-
associated CNAs was assessed, 10 samples were found to
have 9 or more of these CNAs. Of these 10 samples 80%
(n ¼ 8) have a BRCA1 defect, six samples are BRCA1-mutated
BLCs, one sample a BRCA1-methylated BRCAX BLC, and one
sample a BRCA1-methylated sporadic BLC. The other two sam-
ples are a BRCA2-mutated BLC and a BRCAX BLC of which no
further information is available. The frequency plot of gains
and losses for the six BRCA1-mutated BLCs shows identical re-
gions and frequencies of CNAs as compared to the low TIL
BRCA1-mutated BLCs from the primary study (Supplemental
file S9B and Figure 2B).
A second dataset consisting of 186 micro-dissected sam-
ples including 39 BRCA1-mutated triple negative and 49 spo-
radic triple negative breast tumors for which aCGH data are
available, was obtained from the Netherlands Cancer Institute
(Validation dataset 3 in Supplemental Figure 1; Schouten et al.,
2013). After copy number analysis of all 186 samples, 9 sam-
ples were found to have 9 or more BRCA1-associated CNAs.
Of these 9 samples 89% (n ¼ 8) have a BRCA1 defect, six are
BRCA1-mutated and two samples BRCA1-methylated. All 9
samples are triple negative breast carcinomas.
Because the number of BRCA1-mutated samples scored as
suchwas lower than expected, copy number analysis was also
performed with less stringent parameters. (for details seesection 2.6) With these settings 22 samples were found to
have 9 or more BRCA1-associated CNAs. Of these samples
77% have a BRCA1 defect; 14 are BRCA1-mutated and three
BRCA1-methylated. For the called BRCA1-mutated samples,
the frequencies and genomic coordinates of CNAs
(Supplemental File S10 panel A) are again highly similar to
those identified in the low TIL BRCA1-mutated BLCs from the
primary dataset (Figure 2B) and the BRCA1-mutated samples
identified as such in the validation dataset 2 (Supplemental
File S9B). However, some differences were also observed.
The frequency by which genome wide CNAs are detected is
again much higher in the BRCA1-called samples compared to
the not called samples. This is most apparent for regions
with copy number losses.
For 19 BRCA1-mutated samples H&E stained sections of
paraffin-embedded tissue were available and scored for TILs.
These samples were scored within the area outlined for
micro-dissection. BRCA1-mutated samples with 9 or more
BRCA1-associated CNAswere found to have a lowermean per-
centage of TILs of 27%, as compared to 41% TILs seen in the
remaining BRCA1-mutated samples (not-called as BRCA1).
Although a clear trend is seen, these results appeared not
significantly different (ManneWhitney; p ¼ 0.101,
supplemental File 10 panel B). Since large numbers of TILs
are often seen at the periphery of the tumor samples where
micro-dissection has taken place, it is often difficult to judge
by the pathologist what the actual TIL percentages are in these
samples. This likely contributes to a less stringent difference
in TIL percentages.
3.6. DNA flow cytometry and shallow whole genome
sequencing
To evaluate if BRCA1-mutated BLCs with high amounts of TILs
harbor identical CNAs as those with low amount of TILs, five
triple negative germ line BRCA1-mutated breast carcinomas
with a TIL percentage of 40% or higher were selected for puri-
fication by flow cytometry. For all samples two cell suspen-
sions from paraffin embedded tissue sections were prepared,
one unsorted (comparable to what is analyzed in the tumors
from the primary dataset), and one sorted into both a tumor
cell fraction and a stromal/immune cell fraction. Sufficient
DNA for all three fractions was obtained for three samples
to be further analyzed by shallow whole genome sequencing.
The resulting Log2 ratios for 166k data points were analyzed
identically to the SNP array data analysis. Figure 4 shows
copy number profiles obtained by shallow whole genome
sequencing analyses for the sorted and unsorted fractions of
the three BRCA1-mutated triple negative breast carcinomas.
Supplemental File S11 shows microscopy images and vimen-
tin versus keratin plots for the three FACS sorted samples.
As expected, the copy number profiles of the unsorted frac-
tions show few chromosomal regionswith copy number gains
matching those regions with the highest mean copy numbers
in the sorted tumor fraction profiles (chromosome 1q, 8q, 9p
and 10p). These copy number profiles resemble the SNP array
copy number profiles for the BLCswith the highest amounts of
TILs. The sorted tumor fraction copy number profiles display
many gains and losses of large chromosomal regions, and
were highly similar to those seen by SNP array analysis for
Figure 4 e Copy number profiles of Paraffin-embedded material of three BRCA1-mutated triple negative breast carcinomas profiled by shallow
WGS. Called CNAs are shown in red (gain) and blue (losses). A, shallow WGS copy number plots of the unsorted cell fraction, and keratin
positive cell fraction (tumor cells) for sample 18231. This sample was scored as 60% TIL. B, shallow WGS copy number plots of the unsorted cell
fraction, and keratin positive cell fraction (tumor cells) for sample 5725. This sample was scored as 40% TIL. C, shallow WGS copy number plots
of the unsorted cell fraction, and keratin positive cell fraction (tumor cells) for sample 11795. This sample was scored as 55% TIL.
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The only notable difference however is copy number loss of
the entire long arm of chromosome 17 instead of copy number
neutral/gain LOH at the BRCA1 locus seen in the low TIL
BRCA1-mutated samples by SNP array analysis.
Nine out of twelve BRCA1-associated CNAs were present in
two of the samples. The remaining sample was found to have
6 BRCA1-associated CNAs. After merging the copy number
profiles of the three unsorted and sorted tumor cell fractions
with the SNP array copy number profiles, this sample (tumor
fraction 18231) with lowest BRCA1-associated CNAs appeared
to cluster together with high CIN luminal B carcinomas,
within a predominantly BLC branch, in unsupervised hierar-
chical clustering of copy number data. Whereas the tumor
fractions of the other two tumors cluster together with the
bulk of the BLCs (Supplemental File S12).4. Discussion
The aim of this study was to identify specific genomic charac-
teristics of germ line BRCA1-mutated breast carcinomas. For
this purpose, genome wide copy number, LOH, gene expres-
sion, and BRCA1 promoter hyper-methylation data were
analyzed for a familial cohort of 120 breast carcinomas. Since
BRCA1-mutated breast carcinomas are primarily of the basal-
like subtype and specific CNAs are known to be associated
with this subtype (Bergamaschi et al., 2006; Jonsson et al.,
2010; Smid et al., 2010), we restricted our main analyses to
this intrinsic subtype. Based on mRNA analysis and subse-
quent assessment of TILs on H&E stained frozen sections, it
appeared that approximately two thirds of the BRCA1-mutated BLCs have TIL percentages of 35% or higher, reaching
85% TILs. Similar observations are made for the BRCAX BLCs.
These TIL percentages were initially underestimatedwhen tu-
mor cell percentages were established for these samples. Dis-
crepancies between TIL percentages as scored by the
pathologist and as measured by mRNA analysis is likely
explained by the large heterogeneity regarding the distribu-
tion of TILs throughout the tumor tissue, which makes objec-
tive scoring very difficult. After sample selection for low levels
of TILs, eight BRCA1-mutated and five BRCAX BLCs remained
for further analysis. In spite of this small sample size, differ-
ential regions of CNAs could be readily identified between
these tumor groups. Three of these regions were reported
before; while five other regions were previously not consid-
ered as significantly associated with BRCA1-mutation status
(Wessels et al., 2002; van Beers et al., 2005; Jonsson et al.,
2005; Joosse et al., 2009; Prat et al., 2014). Moreover, the fre-
quencies of recurring CNAs reach levels of 80e100%, much
higher compared to the analysis of BLCs without the selection
based on TIL percentages as well as literature reported obser-
vations. Exemplary for this is the BRCA1-mutated tumor spe-
cific loss of chromosome 15q11-21, which has been
implicated in the loss of TP53BP1 in BRCA1 related oncogenesis
(Bouwman et al., 2010). In literature, this region was found to
be lost in approximately 35% of BRCA1-mutated tumors
(Wessels et al., 2002; van Beers et al., 2005; Joosse et al.,
2009). Our initial observations yielded similar results. Howev-
er, after sample selection, this frequency increased to 100% in
the BRCA1-mutated BLCs.
The eight differential CNAs proved to be capable of
discriminating between the BRCA1-mutated and BRCAX
BLCs with low amount of TILs. Together with the four most
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capable of discriminating between BRCA1-mutated BLCs and
breast carcinomas of other subtypes in our dataset as well.
These results were validated in two independent cohorts,
typically identifying one third of the BRCA1-mutated BLCs as
such, i.e. without taking TILs into account. This is in line
with our findings that approximately two thirds of the
BRCA1-mutated BLCs exhibit extensive lymphocytic infiltra-
tion. Interestingly, in both validation-sets, a number of spo-
radic basal-like/triple negative breast carcinomas reported to
have BRCA1 promoter hyper-methylation are also scored as
BRCA1-like. This suggests that at least a proportion of BRCA1
promoter hyper-methylated breast carcinomas follow an
oncogenic pathway leading to similar CNAs as observed in
BRCA1 germ line mutated BLCs.
The observed homogeneity of CNAs in BRCA1-mutated
BLCs implies that BRCA1 driven oncogenesis essentially leads
to similar CNAs in most BRCA1-mutated BLCs. Obviously, the
ability to measure these BRCA1-related CNAs depends on the
tumor cell percentage of the sample, especially in relation to
the quantity of TILs within these carcinomas. However, a
biased selection could have occurred for a subgroup of
BRCA1-mutated BLCs with low TILs characterized by specific
CNAs favoring the escape of immune system responses. To
address this we performedmulti-parameter DNA flow cytom-
etry analysis of three germ line BRCA1-mutated triple negative
breast carcinomas which were selected for high amounts of
TILs. The copy number profiles obtained by shallow whole
genome sequencing (WGS) of the sorted tumor fractions
were highly similar to those of BRCA1-mutated BLCs with
low amounts of TILs, except for the striking observation that
the sorted tumor fractions of the high TIL cases showed a
loss of the complete long arm of chromosome 17, instead of
copy neutral LOH or copy gain with LOH observed in the low
TIL cases. This difference in acquiring complete BRCA1 defi-
ciencymay thus be somehow linked to the immune response.
A well known difficulty in DNA-copy-number determina-
tion by aCGH and SNP array analyses is variable tumor purity
due to normal DNA contamination. Other such problems arise
from intra-tumor heterogeneity, aneuploidy/polyploidy and
technical artifacts. For these reasons various methodologies
have been proposed to deal with such issues (see e.g. Popova
et al., 2009; Yau et al., 2010). However, such methods have
not been applied in genomic profiling of BRCA1-mutated
breast carcinomas. To assess the impact of such methodolo-
gies on our data we have analyzed all BRCA1-mutated BLCs
with the Tumor Aberration Prediction Suite (TAPS) software
package which is recommended for the identification of allele
specific copy number aberrations in samples with low tumor
percentages (Rasmussen et al., 2011). Overall, the resulting
CNAprofileswere found to be highly similar to our primary re-
sults (data not shown). Therefore we believe that in silico data
‘cleaning’ does not adequately resolve the effect of relative
large quantities of TILs on genomic profiling, at least in our
samples, and that therefore FACSmethods to clean the biolog-
ical signal are preferred. This is best seen by comparing the
genomic profiles generated after FACS sorting and subsequent
shallow whole genome sequencing analyses. The genomic
profiles in the unsorted tumor fractions display, besides a
few apparently low-level copy number gains, flat-line copynumber profiles. Whereas the sorted tumor fractions show
many copy number gains and losses (Figure 4).
In summary, we noticed that the effect of TILs on genomic
profiling of tumors is often not taken into account potentially
leading to misinterpretation of data, at least in breast cancer
research focused on BLCs and therefore BRCA1-mutated
breast tumors. Micro-dissection of tumor material can be
used to exclude TILs located at the outer borders of the tumor
cell mass. However, TILs located in between tumor cells
cannot be removed in this way. Consequently, the use of
genomic classifiers on tumor material to identify potential
BRCA1-mutated patients, by for example Multiplex Ligation-
dependent Probe Amplification (MLPA) (Lips et al., 2011b), or
to evaluate BRCA1 variants of unknown significance most
likely suffers from the consequences of very high quantities
of TILs in a sizeable fraction of patients. Care must be taken
so that BRCA1-mutated breast carcinomas with high quanti-
ties of TILs are not misinterpreted.5. Conclusion
In conclusion, the presence of large quantities of TILs in espe-
cially basal-like breast carcinomas (BLCs) impacts on copy
number (and LOH) profiling by SNP, aCGH and shallow WGS.
Based on differential CNAs between BRCA1-mutated and
BRCAX BLCswith low amounts of TILs, known aswell as novel
BRCA1 tumor specific CNAs were identified. A simple scoring
method based on these CNAs was constructed and capable
of identifying BRCA1-mutated basal-like/triple negative breast
carcinomas with high specificity. A similar analysis with a
larger sample set in combination with a machine learning
approach could fine-tune these results. In addition, future
studies may give insight into the differences between
BRCA1-mutated BLCs with differential mechanisms for losing
the wild-type BRCA1-allele, i.e. either by copy neutral/gain
LOH or copy loss. Such studies should preferably include a se-
lection step specifically aimed at selecting for samples with
low quantities of TILs, or otherwise diminish the effect on
genomic profiling of these cells for example by multi-
parameter DNA flow cytometry as shown in this study and
other studies performed on cervical and colorectal carci-
nomas (Middeldorp et al., 2008; Mehta et al., 2009). Also, this
approach will most likely prove valuable in next generation
sequencing studies on tumor material with high number of
TILs. The CNAs specific for BRCA1-mutated BLCs will facilitate
the identification of genes contributing to BRCA1 driven onco-
genesis, which could ultimately lead to a better understanding
of the etiology of BRCA1 tumors and possibly to novel thera-
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